Strong sales of its shingles vaccine Shingrix has already seen GSK upgrade its forecasts for 2023.
The pharmaceutical giant now expects turnover to increase by 8-10%, up from the previous estimate of 6-8%, and adjusted operating profit growth of 11-13%, up from 10-12%. Adjusted EPS growth is also expected to rise by 14-17%, up from 12-15%.
Confirmation of those numbers will probably be enough for investors in next week’s third-quarter update, though the UK pharma might quantify what all the recent regulatory good news for its RSV vaccines means financially.
GSK also settled recently with a group of litigants in California over its Zantac heartburn litigation, prompting analysts to suggest the issue might be settled completely by the first quarter of 2024 for “US$5bn or less”.
Shares are trading at 1,457p, largely unchanged from the start of the year.